<html>
<head>
	<title>wint20170612_8k.htm</title>
	<!-- Created by RDG HTML Converter v1.1.0.0 6/12/2017 1:07:12 PM --><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10px; margin-right: 10px; cursor: auto;">
<p style="font-family:Times New Roman, Times, serif;font-size:12pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>&nbsp;</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>UNITED STATES</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;font-variant:small-caps;margin:0pt;text-align:center;"><b>WASHINGTON, D.C. </b><font style="font-family:Times New Roman, Times, serif;font-size:10pt;"><b>20549</b></font></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<hr align="center" style="width: 30%;height: 1.5px;color: #000000;background-color: #000000;border: none;">
<p>&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>FORM 8-K</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CURRENT REPORT</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>June 12</b><font style="font-family:Times New Roman, Times, serif;font-size:10pt;"><b>, 2017</b></font></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Date of Report (Date of earliest event reported)</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:24pt;margin:0pt;text-align:center;"><b>Windtree Therapeutics, Inc.</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Exact name of registrant as specified in its charter)</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="TBL1" style="width:100%;text-indent:0;font-family:Times New Roman, Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:33%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Delaware</b></p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>000-26422</b></p>
			</td>
			<td style="vertical-align:top;width:33%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>94-3171943</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:33%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">(State or other jurisdiction of incorporation)</p>
			</td>
			<td style="vertical-align:top;width:34%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Commission File Number)</p>
			</td>
			<td style="vertical-align:top;width:33%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">(IRS Employer Identification Number)</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>2600 Kelly Road, Suite 100</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Warrington, Pennsylvania 18976</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Address of principal executive offices)</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(215) 488-9300</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Registrant&#39;s telephone number, including area code)</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Former name or former address, if changed since last report)</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="TBL2" style="width:100%;text-indent:0;font-family:Times New Roman, Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:3.8%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#61551;</p>
			</td>
			<td style="vertical-align:top;width:96.1%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" id="TBL3" style="width:100%;text-indent:0;font-family:Times New Roman, Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:3.8%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#61551;</p>
			</td>
			<td style="vertical-align:top;width:96.1%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" id="TBL4" style="width:100%;text-indent:0;font-family:Times New Roman, Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:3.8%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#61551;</p>
			</td>
			<td style="vertical-align:top;width:96.1%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" id="TBL5" style="width:100%;text-indent:0;font-family:Times New Roman, Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:3.8%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#61551;</p>
			</td>
			<td style="vertical-align:top;width:96.1%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<hr align="left" style="width: 100%;height: 1px;color: #000000;background-color: #000000;border: none;">
<p>&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="TBL6" style="width:100%;text-indent:0;font-family:Times New Roman, Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:13.5%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Item 1.01</b></p>
			</td>
			<td style="vertical-align:top;width:86.5%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u><b>Entry into a Material Definitive Agreement</b></u><font style="font-family:Times New Roman, Times, serif;font-size:10pt;"><b>.</b></font></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:45.8pt;"><font style="font-family:Times New Roman, Times, serif;font-size:10pt;">Effective June 12, 2017 (the &ldquo;<b>Effective Date</b>&rdquo;), Windtree Therapeutics, Inc. (the &ldquo;<b>Company</b>&rdquo;) entered into a License, Development and Commercialization Agreement (&ldquo;<b>License Agreement</b>&rdquo;) with Lee&rsquo;s Pharmaceutical (HK) Ltd., a company organized under the laws of Hong Kong (<b>&ldquo;Lee&rsquo;s</b>&rdquo;). Under the License Agreement, the Company has granted to Lee&rsquo;s an exclusive license with a right to sublicense, (i) to develop and commercialize the Company&rsquo;s KL</font><font style="font-size:7pt;">4</font><font style="font-family:Times New Roman, Times, serif;font-size:10pt;"> surfactant products, including SURFAXIN</font><font style="font-size:7pt;">&reg;</font><font style="font-family:Times New Roman, Times, serif;font-size:10pt;">, which was approved by the U.S. Food and Drug Administration (&ldquo;<b>FDA</b>&rdquo;) in 2012 for the prevention of respiratory distress syndrome (&ldquo;<b>RDS</b>&rdquo;) in premature infants, SURFAXIN LS</font><font style="font-size:7pt;">&trade;</font><font style="font-family:Times New Roman, Times, serif;font-size:10pt;">, the lyophilized dosage form of SURFAXIN; and AEROSURF</font><font style="font-size:7pt;">&reg;</font><font style="font-family:Times New Roman, Times, serif;font-size:10pt;">, the Company&rsquo;s investigative combination drug/device product</font><font style="font-family:Times New Roman, Times, serif;font-size:10pt;"> </font><font style="font-family:Times New Roman, Times, serif;font-size:10pt;">that is designed to deliver aerosolized KL</font><font style="font-size:7pt;">4&nbsp;</font><font style="font-family:Times New Roman, Times, serif;font-size:10pt;">surfactant noninvasively, and (ii) to register and manufacture SURFAXIN and SURFAXIN LS for use in the Licensed Territory, which includes the People&rsquo;s Republic of China (&ldquo;<b>PRC</b>&rdquo;), Hong Kong, Thailand, Taiwan and 12 other countries (the &ldquo;<b>Licensed Territory</b>&rdquo;). In addition, the Company has granted Lee&rsquo;s options to potentially add Japan to the Licensed Territory and to manufacture the Company&rsquo;s aerosol delivery device in the Licensed Territory, in each case subject to conditions set forth in the License Agreement.</font></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Under the License Agreement, <font style="font-family:Times New Roman, Times, serif;font-size:10pt;">Lee&rsquo;s will make an upfront payment to the Company of $1&nbsp;million on or before July 5, 2017. (Lee&rsquo;s also invested $2&nbsp;million in the Company&rsquo;s recent private placement of Convertible Preferred Stock units that was effective February 13, 2017.) The Company also may receive up to $37.5 million in potential&nbsp;</font>clinical, regulatory and commercial <font style="font-family:Times New Roman, Times, serif;font-size:10pt;">milestone payments. The Company also will share in any sublicense income Lee&rsquo;s may receive at a rate equal to low double digits. In addition, Lee&rsquo;s will be responsible for all costs and expenses in and for the Licensed Territory related to development activities, including a planned AEROSURF phase 3 clinical trial, regulatory activities, and commercialization activities.</font></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">T<font style="font-family:Times New Roman, Times, serif;font-size:10pt;">he Company also will be eligible to receive tiered royalties based on a percent of Net Sales, </font>depending on the product,&nbsp;<font style="font-family:Times New Roman, Times, serif;font-size:10pt;">in the range of high single to low-to-mid double digit percentages. Royalties are payable on a country-by-country basis until the latest of (A) the expiration of the last valid patent claim covering the product in the country of sale, (B) the expiration or revocation of any applicable regulatory exclusivity in the country of sale, and (C) ten (10) years after the first commercial sale in the country of sale. Thereafter, in consideration of licensed rights other than patent rights, royalties shall continue for the commercial life of each product and, for the initial three years, shall be in the range of low-to-mid single digits. In addition, in the event that one or more generic products are introduced, the royalty rates will be reduced, subject to certain minimums if the Company has continuing obligations at the time to pay royalties under its in-license agreements. </font></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Under the License Agreement, <font style="font-family:Times New Roman, Times, serif;font-size:10pt;">Lee&rsquo;s will be responsible for all activities related to development, regulatory approval and commercialization of the Company&rsquo;s KL</font><font style="font-size:7pt;">4</font><font style="font-family:Times New Roman, Times, serif;font-size:10pt;"> surfactant and combination drug / device products in the Licensed Territory. Lee&rsquo;s will hold the product licenses for all non-aerosolized products in the Licensed Territory and will seek regulatory approval initially for SURFAXIN and SURFAXIN LS for RDS. The Company will hold the product license in the Licensed Territory (except where prohibited by law) for all aerosolized products and will designate Lee&rsquo;s its exclusive agent and representative to develop and register AEROSURF and other aerosolized products in the name of and on behalf of the Company. Lee&rsquo;s also has agreed that, except as provided in the License Agreement, for a period of ten (10)&nbsp;years beginning with the later of the first commercial sale of the first aerosolized product and the first commercial sale of the first non-aerosolized product in the PRC, it will not develop, register, manufacture, or commercialize any product for the prevention and/or treatment of RDS in premature infants or other diseases and conditions in humans, in either case that administers, utilizes or contains pulmonary surfactant without the Company&rsquo;s prior written consent.</font></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Under <font style="font-family:Times New Roman, Times, serif;font-size:10pt;">the License Agreement, the Company and Lee&rsquo;s will establish a Joint Steering Committee (&ldquo;JSC&rdquo;) to oversee the development, registration and commercialization of the products in the Licensed Territory. In addition, the Company and Lee&rsquo;s will establish a Joint Development Committee to prepare and oversee the development plan for the Licensed Territory, and at the appropriate time, a Joint Commercialization Committee to implement a commercialization plan and oversee the commercialization of approved products in the Licensed Territory.</font></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Lee<font style="font-family:Times New Roman, Times, serif;font-size:10pt;">&rsquo;s may sublicense certain activities under the License Agreement to an affiliate of Lee&rsquo;s, but may not grant sublicenses to unaffiliated third parties without the prior consent of the Company. A sublicensee and a subcontractor may not be a competitor identified by the Company. Sublicenses under the License Agreement do not include the right to further sublicense. In addition, the Company and Lee&rsquo;s plan to negotiate (i)&nbsp;a technology transfer agreement under which the Company will transfer to Lee&rsquo;s the manufacturing processes for SURFAXIN and SURFAXIN LS; (ii) a manufacturing agreement providing for the manufacture of SURFAXIN and SURFAXIN&nbsp;LS by Lee&rsquo;s and giving the Company access to such products outside the Licensed Territory; (iii) a manufacturing and supply agreement providing for the manufacture and supply of AEROSURF drug and medical device components by the Company to Lee&rsquo;s; and (iv) such other agreements and amendments as may be necessary for the parties to perform their obligations under the License Agreement.</font></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The term of the License Agreement commenced on the Effective Date and will continue on a country-by-country basis <font style="font-family:Times New Roman, Times, serif;font-size:10pt;">for the commercial life of the products. Either party may terminate the License Agreement in the event of bankruptcy or a material breach of the License Agreement by the other party that remains uncured for a period of sixty (60)&nbsp;days. In addition, either party may terminate the License Agreement in its entirety or with respect to any individual product or country if a regulatory authority terminates, suspends or discontinues development of a product and such termination, suspension or discontinuance persists for a period in excess of eighteen (18) months. Upon termination of the License Agreement in its entirety or with respect to a particular product or country, generally all related rights and licenses granted to Lee&rsquo;s will terminate, all rights under the Company&rsquo;s technology will revert to the Company, and Lee&rsquo;s will cease all use of the Company&rsquo;s technology. </font></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The foregoing description of the <font style="font-family:Times New Roman, Times, serif;font-size:10pt;">License Agreement does not purport to be complete and is qualified in its entirety by reference to the License Agreement which is expected to be filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) as an exhibit to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. The License Agreement will be filed to provide investors and the Company&rsquo;s stockholders with information regarding the terms thereof and in accordance with applicable rules and regulations of the SEC. Pursuant to the License Agreement, each of the Company and Lee&rsquo;s made customary representations, warranties and covenants and agreed to indemnify each other for certain losses arising out of breaches of such representations, warranties, covenants and other specified matters. The representations, warranties and covenants were made by the parties to and solely for the benefit of each other and any expressly intended third party beneficiaries in the context of all of the terms and conditions of the agreements and in the context of the specific relationship between the parties. Accordingly, investors and stockholders should not rely on the representations, warranties and covenants. Furthermore, investors and stockholders should not rely on the representations, warranties and covenants as characterizations of the actual state of facts or continuing intentions of the parties, since they were only made as of the date of the agreements. Information concerning the subject matter of such representations, warranties and covenants may change after the date of the agreements, which subsequent information may or may not be fully reflected in the Company&rsquo;s reports or other filings with the Commission.</font></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="TBL7" style="width:100%;text-indent:0;font-family:Times New Roman, Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:15.4%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Item </b><font style="font-family:Times New Roman, Times, serif;font-size:10pt;"><b>8</b><b>.01</b><b>.</b></font></p>
			</td>
			<td style="vertical-align:top;width:84.6%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Other Events.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">Reference is made to Item 1.01. <font style="font-family:Times New Roman, Times, serif;font-size:10pt;">On June 12, 2017, the Company issued a press release and announced the execution and delivery of the License Agreement described above. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</font></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">In addition, t<font style="font-family:Times New Roman, Times, serif;font-size:10pt;">he Company will host a conference call and webcast (including a slide presentation) at 8:00 a.m. EDT on Tuesday, June 13, 2017 to discuss the License Agreement and answer questions. The live webcast, including a slide presentation, can be accessed at http://windtreetx.investorroom.com/events . To participate in the live call and take part in the question and answer session, dial (844) 802-2436 (domestic) or (412) 317-5129 (international). </font></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">A replay of the conference call will be accessible one hour after completion through June 20, 2017 by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and referencing conference number 10108999. An archive of the webcast can be accessed on the Company<font style="font-family:Times New Roman, Times, serif;font-size:10pt;">&rsquo;s website at http://windtreetx.investorroom.com/events. </font></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-108pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="TBL8" style="width:100%;text-indent:0;font-family:Times New Roman, Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:9.6%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Item 9.01.</b></p>
			</td>
			<td style="vertical-align:top;width:90.4%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><b>Financial Statements and Exhibits.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="TBL9" style="width:91.8%;text-indent:0;font-family:Times New Roman, Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:14.1%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:58pt;margin-top:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:9.4%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">(d)</p>
			</td>
			<td style="vertical-align:top;width:76.5%;">
			<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibits</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:14.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:9.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:76.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:14.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:9.4%;">
			<p style="background-color:#FFFFFF;font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">99.1</p>
			</td>
			<td style="vertical-align:top;width:76.5%;">
			<p style="background-color:#FFFFFF;font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Press release dated <font style="font-family:Times New Roman, Times, serif;font-size:10pt;">June 12, 2017</font></p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-108pt;"><b>Cautionary Note Regarding Forward-looking Statements:</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-108pt;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">To the extent that statements in this Current Report on Form 8-K are not strictly historical, including statements as to business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company<font style="font-family:Times New Roman, Times, serif;font-size:10pt;">&rsquo;s product development or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this Current Report are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Such risks and others are further described in the Company&rsquo;s filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.</font></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>SIGNATURES</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -9pt; text-align: left; text-indent: 45pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:53.8%;"><b><font style="font-family:Times New Roman, Times, serif;font-size:10pt;">Windtree Therapeutics, Inc.</font></b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 351pt; text-indent: -18pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="font-family:Times New Roman, Times, serif;font-size:10pt;">By: <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Craig Fraser</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 387pt; text-indent: -18pt;"><font style="font-family:Times New Roman, Times, serif;font-size:10pt;">Craig Fraser</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 387pt; text-indent: -18pt;"><font style="font-family:Times New Roman, Times, serif;font-size:10pt;">President and Chief Executive Officer</font></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:65.4%;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-306pt;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date: <font style="font-family:Times New Roman, Times, serif;font-size:10pt;">June 12, 2017</font></p>
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "wint20170612_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 31691}]
{"company-data": {"conformed-name": "WINDTREE THERAPEUTICS INC /DE/", "cik": "0000946486", "assigned-sic": "2836", "irs-number": "943171943", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-26422", "film-number": "17907316"}, "business-address": {"street1": "2600 KELLY ROAD", "street2": "SUITE 100", "city": "WARRINGTON", "state": "PA", "zip": "18976", "phone": "2154889300"}, "mail-address": {"street1": "2600 KELLY ROAD", "street2": "SUITE 100", "city": "WARRINGTON", "state": "PA", "zip": "18976"}, "former-company": [{"former-conformed-name": "DISCOVERY LABORATORIES INC /DE/", "date-changed": "19971201"}, {"former-conformed-name": "ANSAN PHARMACEUTICALS INC", "date-changed": "19961121"}, {"former-conformed-name": "ANSAN INC", "date-changed": "19950609"}]}
wint20170612_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
June 12
, 2017
Date of Report (Date of earliest event reported)
Windtree Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
000-26422
94-3171943
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification Number)
2600 Kelly Road, Suite 100
Warrington, Pennsylvania 18976
(Address of principal executive offices)
(215) 488-9300
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01
Entry into a Material Definitive Agreement
.
Effective June 12, 2017 (the "
Effective Date
"), Windtree Therapeutics, Inc. (the "
Company
") entered into a License, Development and Commercialization Agreement ("
License Agreement
") with Lee's Pharmaceutical (HK) Ltd., a company organized under the laws of Hong Kong (
"Lee's
"). Under the License Agreement, the Company has granted to Lee's an exclusive license with a right to sublicense, (i) to develop and commercialize the Company's KL
4
surfactant products, including SURFAXIN
®
, which was approved by the U.S. Food and Drug Administration ("
FDA
") in 2012 for the prevention of respiratory distress syndrome ("
RDS
") in premature infants, SURFAXIN LS
™
, the lyophilized dosage form of SURFAXIN; and AEROSURF
®
, the Company's investigative combination drug/device product
that is designed to deliver aerosolized KL
4
surfactant noninvasively, and (ii) to register and manufacture SURFAXIN and SURFAXIN LS for use in the Licensed Territory, which includes the People's Republic of China ("
PRC
"), Hong Kong, Thailand, Taiwan and 12 other countries (the "
Licensed Territory
"). In addition, the Company has granted Lee's options to potentially add Japan to the Licensed Territory and to manufacture the Company's aerosol delivery device in the Licensed Territory, in each case subject to conditions set forth in the License Agreement.
Under the License Agreement,
Lee's will make an upfront payment to the Company of $1 million on or before July 5, 2017. (Lee's also invested $2 million in the Company's recent private placement of Convertible Preferred Stock units that was effective February 13, 2017.) The Company also may receive up to $37.5 million in potential
clinical, regulatory and commercial
milestone payments. The Company also will share in any sublicense income Lee's may receive at a rate equal to low double digits. In addition, Lee's will be responsible for all costs and expenses in and for the Licensed Territory related to development activities, including a planned AEROSURF phase 3 clinical trial, regulatory activities, and commercialization activities.
T
he Company also will be eligible to receive tiered royalties based on a percent of Net Sales,
depending on the product,
in the range of high single to low-to-mid double digit percentages. Royalties are payable on a country-by-country basis until the latest of (A) the expiration of the last valid patent claim covering the product in the country of sale, (B) the expiration or revocation of any applicable regulatory exclusivity in the country of sale, and (C) ten (10) years after the first commercial sale in the country of sale. Thereafter, in consideration of licensed rights other than patent rights, royalties shall continue for the commercial life of each product and, for the initial three years, shall be in the range of low-to-mid single digits. In addition, in the event that one or more generic products are introduced, the royalty rates will be reduced, subject to certain minimums if the Company has continuing obligations at the time to pay royalties under its in-license agreements.
Under the License Agreement,
Lee's will be responsible for all activities related to development, regulatory approval and commercialization of the Company's KL
4
surfactant and combination drug / device products in the Licensed Territory. Lee's will hold the product licenses for all non-aerosolized products in the Licensed Territory and will seek regulatory approval initially for SURFAXIN and SURFAXIN LS for RDS. The Company will hold the product license in the Licensed Territory (except where prohibited by law) for all aerosolized products and will designate Lee's its exclusive agent and representative to develop and register AEROSURF and other aerosolized products in the name of and on behalf of the Company. Lee's also has agreed that, except as provided in the License Agreement, for a period of ten (10) years beginning with the later of the first commercial sale of the first aerosolized product and the first commercial sale of the first non-aerosolized product in the PRC, it will not develop, register, manufacture, or commercialize any product for the prevention and/or treatment of RDS in premature infants or other diseases and conditions in humans, in either case that administers, utilizes or contains pulmonary surfactant without the Company's prior written consent.
Under
the License Agreement, the Company and Lee's will establish a Joint Steering Committee ("JSC") to oversee the development, registration and commercialization of the products in the Licensed Territory. In addition, the Company and Lee's will establish a Joint Development Committee to prepare and oversee the development plan for the Licensed Territory, and at the appropriate time, a Joint Commercialization Committee to implement a commercialization plan and oversee the commercialization of approved products in the Licensed Territory.
Lee
's may sublicense certain activities under the License Agreement to an affiliate of Lee's, but may not grant sublicenses to unaffiliated third parties without the prior consent of the Company. A sublicensee and a subcontractor may not be a competitor identified by the Company. Sublicenses under the License Agreement do not include the right to further sublicense. In addition, the Company and Lee's plan to negotiate (i) a technology transfer agreement under which the Company will transfer to Lee's the manufacturing processes for SURFAXIN and SURFAXIN LS; (ii) a manufacturing agreement providing for the manufacture of SURFAXIN and SURFAXIN LS by Lee's and giving the Company access to such products outside the Licensed Territory; (iii) a manufacturing and supply agreement providing for the manufacture and supply of AEROSURF drug and medical device components by the Company to Lee's; and (iv) such other agreements and amendments as may be necessary for the parties to perform their obligations under the License Agreement.
The term of the License Agreement commenced on the Effective Date and will continue on a country-by-country basis
for the commercial life of the products. Either party may terminate the License Agreement in the event of bankruptcy or a material breach of the License Agreement by the other party that remains uncured for a period of sixty (60) days. In addition, either party may terminate the License Agreement in its entirety or with respect to any individual product or country if a regulatory authority terminates, suspends or discontinues development of a product and such termination, suspension or discontinuance persists for a period in excess of eighteen (18) months. Upon termination of the License Agreement in its entirety or with respect to a particular product or country, generally all related rights and licenses granted to Lee's will terminate, all rights under the Company's technology will revert to the Company, and Lee's will cease all use of the Company's technology.
The foregoing description of the
License Agreement does not purport to be complete and is qualified in its entirety by reference to the License Agreement which is expected to be filed with the Securities and Exchange Commission ("SEC") as an exhibit to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. The License Agreement will be filed to provide investors and the Company's stockholders with information regarding the terms thereof and in accordance with applicable rules and regulations of the SEC. Pursuant to the License Agreement, each of the Company and Lee's made customary representations, warranties and covenants and agreed to indemnify each other for certain losses arising out of breaches of such representations, warranties, covenants and other specified matters. The representations, warranties and covenants were made by the parties to and solely for the benefit of each other and any expressly intended third party beneficiaries in the context of all of the terms and conditions of the agreements and in the context of the specific relationship between the parties. Accordingly, investors and stockholders should not rely on the representations, warranties and covenants. Furthermore, investors and stockholders should not rely on the representations, warranties and covenants as characterizations of the actual state of facts or continuing intentions of the parties, since they were only made as of the date of the agreements. Information concerning the subject matter of such representations, warranties and covenants may change after the date of the agreements, which subsequent information may or may not be fully reflected in the Company's reports or other filings with the Commission.
Item
8
.01
.
Other Events.
Reference is made to Item 1.01.
On June 12, 2017, the Company issued a press release and announced the execution and delivery of the License Agreement described above. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
In addition, t
he Company will host a conference call and webcast (including a slide presentation) at 8:00 a.m. EDT on Tuesday, June 13, 2017 to discuss the License Agreement and answer questions. The live webcast, including a slide presentation, can be accessed at http://windtreetx.investorroom.com/events . To participate in the live call and take part in the question and answer session, dial (844) 802-2436 (domestic) or (412) 317-5129 (international).
A replay of the conference call will be accessible one hour after completion through June 20, 2017 by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and referencing conference number 10108999. An archive of the webcast can be accessed on the Company
's website at http://windtreetx.investorroom.com/events.
Item 9.01.
Financial Statements and Exhibits.
(d)
Exhibits
99.1
Press release dated
June 12, 2017
Cautionary Note Regarding Forward-looking Statements:
To the extent that statements in this Current Report on Form 8-K are not strictly historical, including statements as to business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company
's product development or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this Current Report are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Such risks and others are further described in the Company's filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Windtree Therapeutics, Inc.
By:
/s/ Craig Fraser
Craig Fraser
President and Chief Executive Officer
Date:
June 12, 2017